ACE1831
Non-Hodgkin's Lymphoma
About Acepodia
Acepodia is developing first-in-class, allogeneic cell therapies using its proprietary Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs Conjugation (AD2C) platforms. Founded in 2017 with deep roots in Nobel laureate Carolyn Bertozzi's lab, the company has advanced multiple programs into Phase 1 clinical trials for oncology and autoimmune indications and secured strategic partnerships with industry leaders like Pfizer. Its strategy leverages a unique chemical conjugation approach to create readily available 'immune cell engagers' targeting both hematologic malignancies and solid tumors, aiming to democratize cell therapy access.
View full company profileAbout Acepodia
Acepodia is developing first-in-class, allogeneic cell therapies using its proprietary Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs Conjugation (AD2C) platforms. Founded in 2017 with deep roots in Nobel laureate Carolyn Bertozzi's lab, the company has advanced multiple programs into Phase 1 clinical trials for oncology and autoimmune indications and secured strategic partnerships with industry leaders like Pfizer. Its strategy leverages a unique chemical conjugation approach to create readily available 'immune cell engagers' targeting both hematologic malignancies and solid tumors, aiming to democratize cell therapy access.
View full company profileTherapeutic Areas
Other Non-Hodgkin's Lymphoma Drugs
| Drug | Company | Phase |
|---|---|---|
| BI-1206 | BioInvent International | Phase 1/2 |
| SP-3164 | Sumitomo Pharma | Phase 1/2 |